Thus, integrated genomic and functional approaches can move TP53 mutant AML patient stratification beyond fixed risk scoring systems and create a dynamic, personalized model that guides therapy selection, predicts response, and monitors disease evolution over time. Here, TP53 is linked to acute myeloid leukemia.